Humanin

Humanin (also known as HN, Humanin-G, S14G-Humanin) is a prominently researched experimental compound classified strictly within the Mitochondrial Peptide framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it 21-amino acid mitochondrial-derived peptide (MOTS-c sibling peptide) encoded in the 16S rRNA gene of mitochondrial DNA. Binds formyl peptide receptor-like 1 (FPRL1/FPR2) and the gp130 co-receptor complex, activating STAT3 and PI3K/Akt survival signaling. Potently inhibits Bax-mediated apoptosis, protects neurons against amyloid-beta toxicity, and improves insulin sensitivity. Circulating levels decline significantly with age. with a documented biological half-life of roughly 0.5 hours, In preclinical investigative trials and independent academic studies, researchers utilizing Humanin have documented significant, quantifiable biological outcomes, primarily focusing on neuroprotection, anti-apoptosis, insulin sensitization, longevity, alzheimer's protection. Typical research protocols investigate administering 50 to 200mcg via subq pathways daily. However, it is critically important to understand that while Humanin demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.